Mts105 for Advanced Hepatocellular Carcinoma

This is the first-in-human trial of MTS105 (mRNA-LNP). The goal of this clinical trial is to evaluate the safety, tolerability of intravenous injection of MTS105 in advanced hepatocellular carcinoma.

Trial Details

NCT ID
NCT06689540
Phase
PHASE1
Sponsor
Shen Lin
Status
RECRUITING
Cancer Type
Hepatocellular Carcinoma (HCC) Liver Cancer
Interventions
  • MTS105
Locations (sample)
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • Histologically or cytologically confirmed diagnosis of hepatocellular carcinoma (HCC), excluding fibrolamellar or sarcomatoid subtypes, as well as …
  • Positive for GPC3 expression per immunohistochemical (IHC) staining.
  • Failure of standard systemic therapies, including at least one immune checkpoint inhibitor and one targeted therapy (Tyrosine Kinase Inhibitors, an…
  • Presence of a measurable tumor lesion (per RECIST/ mRECIST criteria).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hepatocellular Carcinoma (HCC) Liver Cancer Trials on Trialify →